MindMed director Stephen Hurst resigns from board effective immediately

Definium Therapeutics, Inc.

Stephen Hurst resigned as director of Mind Medicine (MindMed) on January 5, 2022.
Resignation is not based on any disagreement with the Company or management.
Hurst had served on the board since February 2020.
CEO Robert Barrow thanked Hurst for his contributions and strategic guidance.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stephen Hurst

Director

DFTX · Definium Therapeutics, Inc.

Effective: 2022-01-05
Filed: January 7, 2022, 6:59 PM ET

On January 5, 2022, Mr. Stephen Hurst, a member of the board of directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”), notified the Board of his decision to resign from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Hurst resigned as Director at Definium Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On January 5, 2022, Mr. Stephen Hurst, a member of the board of directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”), notified the Board of his decision to resign from the Board, effective immediately.

View on SEC.gov

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-002314

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.